Does Farxiga Affect Blood Pressure?
Yes, Farxiga (dapagliflozin) modestly lowers blood pressure, typically reducing systolic blood pressure by approximately 2-4 mmHg, but this effect is minimal and does not cause clinically significant hypotension in most patients.
Blood Pressure Effects
The blood pressure-lowering effect of dapagliflozin is consistent across multiple clinical contexts:
In heart failure patients: Dapagliflozin reduces blood pressure by an average of approximately 2 mmHg 1, with minimal to no effect on blood pressure and no excess risk of symptomatic hypotension 2. This makes it particularly well-suited for initiation even in hospitalized patients where blood pressure concerns might otherwise limit therapy.
In chronic kidney disease: The DAPA-CKD trial demonstrated that dapagliflozin reduced systolic blood pressure by 3.6 mmHg at Week 2, with a sustained reduction of 2.9 mmHg maintained throughout the trial 3. The effect was present in patients both with diabetes (3.2 mmHg reduction) and without diabetes (2.3 mmHg reduction). Diastolic blood pressure decreased by approximately 1.0 mmHg 3.
In diabetic kidney disease: A 12-week study showed nighttime systolic blood pressure declined by 3.0 mmHg, with improvements in circadian blood pressure rhythm and increased prevalence of normal dipping patterns 4. Importantly, only one patient experienced a drop in nighttime systolic blood pressure below 90 mmHg, indicating a favorable safety profile 4.
Clinical Significance and Safety
The blood pressure reduction with dapagliflozin is clinically modest and generally does not require dose adjustments of other medications or cause symptomatic hypotension. Key safety considerations include:
The FDA label notes that in patients ≥65 years of age, a higher proportion treated with dapagliflozin for glycemic control had adverse reactions of hypotension, though this remains uncommon 5.
Patients with diabetes and renal impairment using dapagliflozin may be more likely to experience hypotension and may be at higher risk for acute kidney injury secondary to volume depletion 5.
Despite blood pressure lowering, there is no excess risk of symptomatic hypotension compared to placebo in major trials 2.
Mechanism of Blood Pressure Reduction
The blood pressure-lowering effect occurs through mechanisms beyond simple natriuresis. A mechanistic study (DAPASALT) demonstrated that dapagliflozin reduced blood pressure by 6.8 mmHg at Day 4 and 6.5 mmHg at Day 14 without increasing sodium excretion, suggesting the effect occurs through alternative mechanisms such as reduced sympathetic nervous system activity, improved vascular function, or other hemodynamic changes 6.
Practical Implications
Do not withhold dapagliflozin due to concerns about blood pressure lowering in patients with systolic blood pressure >100-110 mmHg, as the effect is modest and the cardiovascular and renal benefits far outweigh this minor reduction.
Monitor blood pressure in elderly patients and those with baseline hypotension, but routine dose adjustments of antihypertensive medications are typically not necessary when initiating dapagliflozin.
The blood pressure effect is consistent across patient populations, including those with heart failure (both reduced and preserved ejection fraction), chronic kidney disease, and diabetes 7, 8, 9.
Benefits on cardiovascular and renal outcomes are evident across the spectrum of baseline blood pressure 3, meaning the drug's efficacy is not dependent on baseline blood pressure levels.